文献速递心力衰竭与心肌病血脂与心血管预防

2型糖尿病是射血分数保留心衰进展的可改变风险因素吗?

Is Type 2 Diabetes a Modifiable Risk Factor for the Evolution and Progression of Heart Failure With a Preserved Ejection Fraction?
PubMed 文献 · J Am Coll Cardiol · 2025-09-17

该综述探讨2型糖尿病与射血分数保留心衰(HFpEF)的关联机制,认为高血糖本身并非主要驱动因素,而中心性肥胖和内脏脂肪堆积是核心中介。降低血糖的多种药物未减少心衰风险,而胰高血糖素样肽受体激动剂、SGLT2抑制剂及减重手术通过改善脂肪生物学降低HFpEF风险。结论提示糖尿病相关HFpEF主要经超额脂肪中介,治疗应针对肥胖而非高血糖。

要点

  • 2型糖尿病与HFpEF的关联主要由中心性肥胖和内脏脂肪增加介导,而非高血糖本身。
  • 胰岛素、磺脲类、DPP-4抑制剂和噻唑烷二酮类降糖未降低心衰风险。
  • GLP-1受体激动剂和SGLT2抑制剂的心脏获益不依赖于糖尿病存在或降糖效应。

核心结论

  • 糖尿病相关HFpEF主要经超额脂肪中介,针对肥胖而非高血糖的治疗才能使糖尿病成为可改变风险因素。

研究设计与样本

  • 综述类文章,检索范围未明确报告。

主要发现

  • 实验模型中与2型糖尿病相关的HFpEF通常伴随脂肪过多。
  • 流行病学研究显示2型糖尿病与HFpEF的关联主要经中心性肥胖和内脏脂肪增加中介。
  • 糖尿病心脏的主要代谢缺陷是脂质过载,而非葡萄糖摄取受损或胰岛素抵抗。
  • 脂肪过多通过分泌促炎脂肪因子导致钠潴留、心脏脂肪变性和纤维化。
  • GLP-1受体激动剂和SGLT2抑制剂降低HFpEF风险或进展,但获益与糖尿病存在或降糖效应无关。

关键数值与推荐

  • 胰岛素、磺脲类、DPP-4抑制剂和噻唑烷二酮类降糖未降低心衰风险。
  • 减重手术减轻内脏肥胖和2型糖尿病并降低HFpEF风险。

临床怎么用

  • 对2型糖尿病合并HFpEF患者,治疗应针对肥胖和内脏脂肪而非仅降糖。
  • 可考虑使用GLP-1受体激动剂或SGLT2抑制剂以降低HFpEF风险或进展。
  • 减重手术可能通过减轻内脏肥胖降低HFpEF风险。

局限性

  • 综述未报告系统检索策略和纳入标准。
  • 多数证据来自实验模型和流行病学研究,因果推断受限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Type 2 diabetes is associated with an increased risk of heart failure with a preserved ejection fraction (HFpEF), but it is not clear whether this metabolic disorder is causal or represents a modifiable risk factor. Mechanisms by which diabetes may be associated with HFpEF can be grouped into the following: 1) those related to hyperglycemia and amenable to antihyperglycemic drugs; and 2) those related to the association of type 2 diabetes with obesity and visceral adiposity, and thus, treatable with interventions that reduce adipose tissue mass or improve adipocyte biology. EVIDENCE AGAINST A ROLE FOR HYPERGLYCEMIA: Experimentally, acute and chronic hyperglycemia caused by islet cell destruction can lead to cardiac dysfunction, but these models resemble type 1 (not type 2) diabetes. Heightened levels of environmental glucose can cause enzymatic or nonenzymatic modification of proteins and signaling through the polyol pathway, but interference with these mechanisms has not produce clinical benefits in patients with heart disease and type 2 diabetes. Furthermore, lowering of blood glucose in type 2 diabetes with insulin, sulfonylureas, dipeptidyl peptidase-4 inhibitors and thiazolidinediones has not reduced the risk of heart failure. EVIDENCE FOR A MEDIATING ROLE FOR ADIPOSITY: In marked contrast, experimental models that link type 2 diabetes to HFpEF are typically accompanied by excess adiposity. Epidemiological studies demonstrate that the association between type 2 diabetes and HFpEF is mediated primarily through a common link with central obesity and an expanded visceral fat mass. Changes in the biology of adipocytes as a result of visceral adiposity are sufficient to cause systemic insulin resistance and diabetes. Interestingly, the primary metabolic defect in the diabetic heart is lipid overload, not an impairment in glucose uptake or insulin resistance. Adiposity can promote HFpEF through the secretion of proinflammatory adipokines that lead to sodium retention and cardiac steatosis and fibrosis. Additionally, excess adiposity can drive the production of and enhance cardiac sensitivity to advanced glycation end products. Glucagon-like peptide receptor agonists and sodium-glucose cotransporter reduce the risk or progression of HFpEF, but this benefit is not related by the presence of diabetes or to the glucose-lowering effects of these drugs. Instead, their favorable cardiac effects may be mediated by their action to induce or mimic a state of caloric deprivation, thus restoring adipokine balance and alleviating the state of cardiac steatosis. Similarly, bariatric surgery alleviates both visceral adiposity and type 2 diabetes and reduces the risk of HFpEF. CONCLUSIONS: Taken together, these findings suggest that diabetes-associated HFpEF is mediated primarily through its association with excess adiposity. Diabetes is a modifiable risk factor if treatment is directed toward adiposity rather than hyperglycemia.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Packer M, Lam CSP, Butler J, et al. Is Type 2 Diabetes a Modifiable Risk Factor for the Evolution and Progression of Heart Failure With a Preserved Ejection Fraction? J Am Coll Cardiol. 2025. PMID: 40960442. doi:10.1016/j.jacc.2025.07.052

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。